Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1 -- 2966 2024-02-13 04:09:32 |
2 layout + 7 word(s) 2973 2024-02-18 02:29:14 | |
3 layout Meta information modification 2973 2024-02-20 01:44:28 |

Video Upload Options

Do you have a full video?


Are you sure to Delete?
If you have any further questions, please contact Encyclopedia Editorial Office.
Ali, D.N.; Ali, H.M.; Lopez, M.R.; Kang, S.; Choi, D. Astrocytic GABAergic Regulation in Alcohol Use. Encyclopedia. Available online: (accessed on 18 April 2024).
Ali DN, Ali HM, Lopez MR, Kang S, Choi D. Astrocytic GABAergic Regulation in Alcohol Use. Encyclopedia. Available at: Accessed April 18, 2024.
Ali, Dina N., Hossam M. Ali, Matthew R. Lopez, Shinwoo Kang, Doo-Sup Choi. "Astrocytic GABAergic Regulation in Alcohol Use" Encyclopedia, (accessed April 18, 2024).
Ali, D.N., Ali, H.M., Lopez, M.R., Kang, S., & Choi, D. (2024, February 13). Astrocytic GABAergic Regulation in Alcohol Use. In Encyclopedia.
Ali, Dina N., et al. "Astrocytic GABAergic Regulation in Alcohol Use." Encyclopedia. Web. 13 February, 2024.
Astrocytic GABAergic Regulation in Alcohol Use

Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the central nervous system (CNS). Most GABAergic neurons synthesize GABA from glutamate and release it in the synaptic cleft in the CNS. However, astrocytes can also synthesize and release GABA, activating GABA receptors in the neighboring neurons in physiological and pathological conditions. As the primary homeostatic glial cells in the brain, astrocytes play a crucial role in regulating GABA homeostasis and synaptic neurotransmission. Accumulating evidence demonstrates that astrocytic GABA dysregulation is implicated in psychiatric disorders, including alcohol use disorder (AUD) and major depressive disorder (MDD), the most prevalent co-occurring psychiatric disorders. 

GABA astrocyte alcohol use disorder major depressive disorder GABA transporter GABA receptor

1. Introduction

Alcohol use disorder (AUD) and major depressive disorder (MDD) are the most common co-occurring disorders substantially burdening worldwide well-being socially and financially [1][2][3]. Notably, AUD and MDD share many neurobiological underpinnings of symptoms [4][5][6][7][8][9][10][11]. Among several notable biological factors attributed to the pathophysiology of AUD and MDD, the dysregulation of γ-aminobutyric acid (GABA) levels and GABA receptor-mediated signaling are crucial to understanding specific phenotypes and, thereby, therapeutic targets [12][13][14]. As the primary inhibitory neurotransmitter in the brain, GABA is involved in multiple crucial brain functions such as learning and memory, motor coordination, emotion regulation, sensory processing, addictive behavior, and circadian rhythm [15][16][17][18][19][20][21]. In MDD patients, the biomarkers associated with GABA metabolism and signaling are altered in the cortical region [22]. While it is known that brain GABA deficits are attributed to the etiology of MDD, GABAergic involvement in the molecular mechanisms of AUD is less clear. Chronic alcohol administration decreases GABA-mediated responses in the cortex and nucleus accumbens, while alcohol increases the GABA released into the central nucleus of the amygdala, facilitating GABAergic transmission [23]. Furthermore, alteration in GABAergic signaling has been implicated in alcohol reinforcement effects and compulsive drinking in variable ways [24][25]. While the activation of GABAB receptors is known to decrease the reinforcement actions of alcohol, acute blockade of GABAA receptors can block the motivation for responding to alcohol [26][27][28][29]. GABA and GABA receptors have also been involved in the changes in the reward system associated with acute withdrawal [13][14].

2. Astrocytic Regulation of Gamma-Aminobutyric Acid in the Central Nervous System

GABA exerts its inhibitory effects by interacting with two distinct receptor types: GABAA receptors (GABAAR) and GABAB receptors (GABABR). GABAAR is an ionotropic receptor and ligand-gated ion channel responsible for inhibitory synaptic transmission in the central nervous system (CNS) [30][31][32]. GABABR, a metabotropic receptor, operates at a slower pace through G-protein-coupled mediated signaling [33]. Immunohistochemical analysis of the adult human brain reveals that astrocytes express GABAAR and GABABR at levels comparable to or even more significant than those observed in known GABAergic neurons. Additionally, cultured astrocytes derived from adult human brain tissue confirm the presence of GABAAR and GABABR at both the mRNA and protein levels, establishing their dual GABAergic and GABAceptive characteristics [34]. In primary cell cultures and rodent slices, extracellular GABA can activate astrocytic GABAARs, increasing Cl concentrations in astrocytes. GABA also activates astrocytic GABABRs, mediating slow inhibitory signaling in the brain via the activation of Gi/o-type G-proteins, leading to the inhibition of adenylyl cyclase. The activation of astrocytic GABABRs increases intracellular Ca2+, which triggers the release of Ca2+ from the intracellular pools. Ca2+ oscillations in astrocytes alter glutamate release and GABA transporter expression. Therefore, astrocytes can internalize GABA via GABA receptors and transporters, indicating their GABAceptive properties [35].
The regulation of GABA levels within the CNS is contingent upon the dynamic interaction between neurons and astrocytes (Figure 1). Both neurons and astrocytes are responsible for the synthesis, release, and reuptake of GABA within synapses. Each process responds to various pathophysiological stimuli to maintain GABA homeostasis. These processes are multifaceted, with distinct mechanisms operating in different cell types and regions of the brain [36][37][38][39][40][41]. Due to their close association with neurons and ability to engage in GABA synthesis, release, and reuptake, astrocytes are now considered pivotal contributors to the intricate task of regulating GABA homeostasis within the CNS [42]. Two glutamate decarboxylases, 1 and 2 (GAD1 and GAD2), produce GABA from glutamate. GAD1 is primarily expressed in neuronal cell bodies, while GAD2 is found in axon terminals [43]. Notably, GAD1, which plays a vital role in GABA synthesis, has also been observed in astrocytes [35][44]. Another crucial precursor of GABA in the CNS is putrescine, metabolized by monoamine oxidase B (MAO-B) and diamine oxidase (DAO). MAO-B is particularly prevalent in astrocytes, especially in cerebellar and striatal astrocytes [45]. Recent studies strongly suggest that GABA synthesis in astrocytes is a predominant factor in regulating GABA levels, suggesting that astrocytes are GABAergic cells [35].
Figure 1. Astrocyte–GABAergic neuron interaction. GABA undergoes extensive recycling between neurons and astrocytes, a process coordinated and regulated by cell-specific transporters and enzymes. Within astrocytes, GABA and glutamate are metabolized, supporting the synthesis of the non-neuroactive amino acid glutamine. Astrocyte-derived glutamine is taken up by neurons and converted to glutamate by phosphate-activated glutaminase (PAG) to replenish the neurotransmitter pool. Sodium-coupled neutral amino acid transporters (SNATs) facilitate glutamate transfer. Astrocytes synthesize GABA from glutamate through a glutamate decarboxylase (GAD)-dependent pathway. Putrescine serves as another precursor for GABA, and monoamine oxidase B (MAO-B) and diamine oxidase (DAO) are the key enzymes in this pathway. Additionally, the BEST1 (bestrophin 1) channel mediates GABA release. GABA transporters recycle excess GABA from the synapse through uptake into neurons and astrocytes. Astrocytes express GAT1 and GAT3, while GABAergic neurons express GAT1. Following uptake, intracellular GABA is metabolized by the enzymes GABA transaminase (GABA-T) and through the intermediate succinate semi-aldehyde by the enzyme succinate semi-aldehyde dehydrogenase (SSADH). This figure was created with (accessed on 17 November 2023).
The release of GABA from astrocytes occurs through three distinct mechanisms: calcium-dependent vesicular exocytosis, direct release into the extracellular space via GABA transporters (GATs) in reverse mode, or through GABA-permeable channels [37][46][47]. GATs function as secondary active electrogenic transporters and utilize sodium and chloride ion exchange with GABA uptake. Although the primary role of GATs is to remove excess GABA from the extracellular space, they were found to act in reverse mode, releasing GABA into the extracellular space in certain conditions, a function that remains controversial [42][48]. GATs are found in presynaptic neurons and astrocytes, with four known types (GAT1, GAT2, GAT3, and BGT1), among which GAT1 and GAT3 exhibit high affinity for GABA [47][48]. While GAT1 was thought to be primarily expressed in neurons, recent research shows that GAT1 is expressed in cortical and thalamic astrocytes as well. [49][50]. GAT3, on the other hand, is exclusively expressed in astrocytes predominantly localized at the astrocytic processes, modulating tonic inhibitory currents in postsynaptic cells. GAT3 activities influence various astrocytic functions encompassing the regulation of inhibitory synapse efficacy, excitatory neurotransmission, and astrocyte synaptic proximity, underscoring the role of GAT3 as a key glial GABA transporter [51][52]. Interestingly, the genetic ablation of GAT3 is lethal in mice, suggesting its critical role in GABA homeostasis during early embryogenesis and development [53].
Furthermore, astrocytic GABA release is facilitated by permeable membrane channels, such as BEST1, which is a calcium-dependent anion channel and is considered a vital mechanism of astrocytic GABA release [37]. Astrocytic GABA is known to interact with mainly surrounding neurons [35]. A recent study shows that astrocytes sense environmental change and release gliotransmitters, including GABA, to alter neuronal activities [54][55]. Astrocytic GABA can interact with synaptic and extrasynaptic receptors [46][54].
The GABA taken up by astrocytes via GABA transporters is either recycled into the GABA/glutamine cycle, which plays critical roles in GABA metabolism between neurons and astrocytes (Figure 2), or metabolized within mitochondria by the GABA transaminase (GABA-T) enzyme, which is present in both neurons and astrocytes [39][56]. Importantly, research has demonstrated that almost half of the released GABA is taken up and metabolized by astrocytes, underscoring their role in regulating GABA levels in the CNS [53]. Therefore, it is evident that astrocytes are considered essential cells in maintaining GABA homeostasis in the brain.
Figure 2. GABA metabolism. GABA is metabolized through the GABA/glutamate/glutamine cycle, which connects neurotransmitter homeostasis and cellular energy metabolism. Glutamate is the principal biological precursor for GABA through the enzyme glutamate decarboxylase (GAD). GABA is converted to succinic semi-aldehyde, which is metabolized into the tricarboxylic acid (TCA) cycle through the enzyme succinic semi-aldehyde dehydrogenase (SSDAH). GABA, glutamate, and glutamine undergo oxidation within the TCA cycle, actively contributing to energy production in neurons and astrocytes. This figure was created with (accessed on 17 November 2023).

3. Astrocytes and Gamma-Aminobutyric Acid in Alcohol Use Disorder (AUD)

Alcohol use disorder (AUD) is a chronic, relapsing disease characterized by compulsive drug seeking despite negative consequences on an individual’s life [57]. Alcohol (or ethanol) exerts its toxicity through alterations in multiple neurotransmitter systems, including the GABA, serotonin, dopamine, glutamate, acetylcholine, and opioid systems [58]. The neurotransmitter imbalances result in malfunctioning brain circuits responsible for cognitive function, decision making, motivation, reward, affect, and the stress response [59]. Despite the dire health and psychosocial consequences, AUD continues to persist as one of the leading causes of death globally [60][61]. According to the most recent report from the National Institute of Health (NIH), the annual mortality rate due to alcohol-related causes exceeds 140,000 individuals, making it one of the leading four preventable factors contributing to fatalities in the United States [62]. AUD is typically associated with the development of tolerance, dependence, and the impairment of social and occupational functioning [63]. Recent research has suggested a significant role in the facilitation of GABAergic transmission in the addictive properties of alcohol [13][14][64]. It has been proposed that GABA plays a substantial role in the neuroadaptations linked to the progression from controlled alcohol consumption to excessive drinking characterized by dependence and relapse [65][66].
Evidence indicates that alcohol alters GABA-mediated responses in various brain regions, including the cortex and substantia nigra [67]. Recent studies have demonstrated that alterations in GABA transmission are particularly pronounced in regions implicated in the negative reinforcing aspects of alcohol, such as the ventral tegmental area (VTA), globus pallidus (GP), and the amygdala [68][69]. In experiments involving in vitro slice preparations from the central amygdala, acute alcohol exposure enhances GABAA inhibitory postsynaptic currents. In rats chronically exposed to alcohol, an increase in evoked GABA release was observed [70]. Additionally, acute pharmacological inhibition of GABAAR function effectively diminishes the motivation for responding to alcohol [13].
Furthermore, the utilization of selective GABAB agonists has been shown to reduce alcohol self-administration in rats and mitigate the alcohol deprivation effect in alcohol-preferring rats [71]. Additional experiments have revealed that the combination of agonists and antagonists at the GABAAR benzodiazepine site leads to a noteworthy reduction in alcohol administration when administered into the amygdala [72][73][74].
Moreover, research employing pharmacological GABA agonists and antagonists has implicated the GABA system in both the physical and affective symptoms associated with alcohol withdrawal. GABA agonists were found to have the capacity to reduce CNS hyper-flexibility during alcohol withdrawal-induced seizures [75][76][77]. Consistently, GABA mimetics potentiate the sedative and motor effects of alcohol, an effect that was counteracted by GABA antagonists [24]. However, the underlying molecular mechanisms of the central effects of alcohol involving GABA-mediated signaling remain unclear. Notably, recent evidence has highlighted the role of astrocytes in modulating GABA transmission within the brain [36]. Chronic alcohol exposure alters the balance between inhibitory and excitatory neurotransmissions in various brain regions such as the cortex and the striatum [78]. Remarkably, a single astrocyte can modulate up to one million inhibitory and excitatory synapses. Consequently, any disruption to even a small subset of astrocytes can profoundly impact on the delicate balance between excitation and inhibition, ultimately, affecting brain function and behavior [79]. However, additional research may elucidate the precise role of astrocytes in ethanol-induced GABAergic neurotransmission.
An essential aspect of AUD is the disruption of the balance between goal-directed and habitual reward-seeking behaviors. Alcohol is known to exert effects on several signaling systems in the cortico-striatal circuits that may collectively contribute to the impairment of behavioral flexibility and motivate the transition from goal-directed to habitual alcohol drinking [80]. Changes in GABA release, uptake, and GABA receptor signaling across chronic alcohol exposure are critically involved in the acquisition of both goal-directed and habitual behaviors [81]. Studies indicate that chronic alcohol exposure may reduce the expression of GABAAR in the dorsal striatum, a region crucial for forming and expressing stimulus–response habits [82][83]. However, the precise direction in which alterations in GABA release and signaling drive behavior is unknown.
Given the pivotal role of astrocytes in regulating GABAergic transmission, recent studies have investigated the specific role of astrocytic GABAergic signaling in cognition and behavior. Recently, researchers documented that genetic ablation of GABABR in the medial prefrontal cortex astrocytes altered the low gamma oscillations and firing properties of cortical neurons, affecting goal-directed behaviors [84].
Within the striatopallidal circuits, the dorsomedial striatum (DMS) and dorsolateral striatum (DLS) are the primary neural regions responsible for regulating goal-directed and habitual behaviors, respectively [85][86][87]. Nevertheless, the external globus pallidus (GPe), an area known to contain a substantial population of astrocytes, assumes a pivotal role in facilitating and coordinating the neurotransmission between the DMS and DLS, making it an integrative center for modulating the flexibility of reward-related behaviors (Figure 3) [88][89]. Notably, extrasynaptic neurotransmitters can trigger astrocyte Ca2+ signaling, and reciprocally, astrocyte Ca2+ signals modulate the function of the neural circuits through various gliotransmitters. Researchers' recent research demonstrated that chemogenetic activation of astrocytes in the DMS differentially regulated striatal medium spiny neuron (MSN) activities and induced a shift from habitual to goal-directed reward-seeking behavior [87][90]. Despite these findings, it has not yet been fully elucidated how astrocytic modulation in the basal ganglia circuit may govern neuronal activities associated with goal-directed and habitual reward-seeking behavior in AUD. While the general role of astrocytes in regulating behavior, excitatory/inhibitory balance, and neuroplasticity in different brain regions is widely recognized, the specific involvement of astrocytic GABA signaling in the context of AUD remains unclear.
Figure 3. GABA transport in the globus pallidus externus (GPe) neurons. The “GPe” accommodates diverse neuronal populations, such as parvalbumin+ neurons and arkypallidal neurons expressing FoxP2+ and LIM homeobox-positive (Lhx6+) neurons. GABAergic neurons in the GPe receive inputs from the striatal indirect pathway medium spiny neurons (iMSNs). The GPe comprises numerous astrocytes capable of releasing neurotransmitters such as ATP, adenosine, glutamate, D-serine, and GABA [68][69]. GABA transporter 3 (GAT3) is an astrocyte-specific transporter responsible for either releasing into the synapse or metabolizing into the GABA/glutamine cycle. This figure was created with (accessed on 17 November 2023).
Researchers' recent study has revealed that GPe astrocyte activity is suppressed during habitual learning in mice. Notably, chemogenetic activation of astrocytes has been shown to reduce habitual behaviors while concurrently enhancing goal-directed reward-seeking behaviors in operant conditioning experiments. Additionally, reseasrchers found that activation of astrocytes reduced the overall activity of GPe neurons, which facilitated the transition from habitual to goal-directed alcohol-seeking behavior as well. Intriguingly, researchers observed an increase in GAT3 mRNA levels during habit formation, and the selective inhibition of GAT3 reversed the impact of astrocytes on the transition from habitual to goal-directed alcohol seeking. Researchers finding indicates that the upregulation of GAT3 in the GPe may deactivate astrocytes, diminishing their inhibitory influence on GPe neurons. These findings underscore the potential essential role of astrocytic GAT3 in regulating reward-related behavioral flexibility within the GPe [91]. Recent evidence supports the idea that GAT3 can govern astrocytic activity [92]. Nevertheless, the underlying mechanisms of GAT3 signaling, potentially involving other neurotransmitters, remain an area yet to be thoroughly explored. Moreover, given the diverse neuronal populations within the GPe, such as parvalbumin-expressing neurons, arkypallidal feedback, and prototypic feedforward neurons (Figure 3), further investigations on the specific changes related to GAT3 activity within distinct GPe cell types are warranted.
GABA transporters have recently garnered increasing attention within the field of addiction research, with a particular focus on GAT3, known for its high expression in astrocytes [52][93]. A recent study has uncovered a decrease in GAT3 mRNA levels in the amygdala, a forebrain structure recognized as a central hub for GABAergic influences on alcohol reinforcement, in alcohol-preferring mice. A reduction in several GABAAR subunits accompanied this decrease. The researchers proposed that this latter observation could indicate heightened GABAergic activity resulting from a decrease in the extracellular clearance of GABA. To further substantiate these findings, the researchers employed a viral GAT3 (Slc6a11) knockdown strategy in a mice group that initially preferred saccharin over alcohol. Their results revealed that, following the full expression of the injected virus in the amygdala, mice with GAT3 knockdown exhibited a shift in behavior from saccharin preference to alcohol preference [64].
The prolonged administration of alcohol, sufficient to induce dependence and escalate alcohol consumption, which is linked to increased GABA release within the amygdala, is accompanied by enhanced sensitivity to GABA agonists [94][95]. A study demonstrated that the microinjection of the GABAA agonist muscimol into the central nucleus of the amygdala (CeA) of alcohol-dependent rats reduced alcohol self-administration. However, this effect was not observed in alcohol nondependent rats [23][96]. Furthermore, a recent study revealed that rats with diminished GAT3 expression in the amygdala exhibited a propensity for persistent alcohol seeking, even when the alcohol was mixed with quinine. These findings suggest that extracellular GABA homeostasis in the amygdala plays a vital role in vulnerability to compulsive alcohol seeking. On the other hand, baclofen, a GABABR agonist, lowers extracellular GABA levels in the amygdala and reduces alcohol consumption in mice and humans [97]. Interestingly, baclofen’s efficacy in diminishing the susceptibility to compulsive drinking and GAT3 expression in the amygdala are inversely correlated. This study showed a positive correlation between GAT3 mRNA levels in the amygdala and increased resistance to quinine in baclofen-treated but not vehicle-treated rats. This implies that baclofen’s effects may be mediated by normalizing impaired GABA clearance resulting from low GAT3 expression in the amygdala. However, it remains unknown whether solely restoring GABA homeostasis in the amygdala is sufficient to reverse compulsive alcohol seeking. Furthermore, additional research may be necessary to elucidate the psychological consequences of manipulating the GABAergic system within the amygdala and whether GAT3 expression is associated with baclofen’s known side effects. Collectively, these findings highlight the pivotal role played by astrocytic GAT3 in the molecular mechanisms of alcohol-seeking behavior and its potential as a therapeutic target for AUD.


  1. Whiteford, H.A.; Degenhardt, L.; Rehm, J.; Baxter, A.J.; Ferrari, A.J.; Erskine, H.E.; Charlson, F.J.; Norman, R.E.; Flaxman, A.D.; Johns, N. Global burden of disease attributable to mental and substance use disorders: Findings from the Global Burden of Disease Study 2010. Lancet 2013, 382, 1575–1586.
  2. Rodgers, B.; Korten, A.E.; Jorm, A.F.; Jacomb, P.A.; Christensen, H.; Henderson, A.S. Non-linear relationships in associations of depression and anxiety with alcohol use. Psychol. Med. 2000, 30, 421–432.
  3. Pedrelli, P.; Shapero, B.; Archibald, A.; Dale, C. Alcohol use and depression during adolescence and young adulthood: A summary and interpretation of mixed findings. Curr. Addict. Rep. 2016, 3, 91–97.
  4. Miguel-Hidalgo, J.J.; Wilson, B.A.; Hussain, S.; Meshram, A.; Rajkowska, G.; Stockmeier, C.A. Reduced connexin 43 immunolabeling in the orbitofrontal cortex in alcohol dependence and depression. J. Psychiatr. Res. 2014, 55, 101–109.
  5. Miguel-Hidalgo, J.J.; Waltzer, R.; Whittom, A.A.; Austin, M.C.; Rajkowska, G.; Stockmeier, C.A. Glial and glutamatergic markers in depression, alcoholism, and their comorbidity. J. Affect. Disord. 2010, 127, 230–240.
  6. Brière, F.N.; Rohde, P.; Seeley, J.R.; Klein, D.; Lewinsohn, P.M. Comorbidity between major depression and alcohol use disorder from adolescence to adulthood. Compr. Psychiatry 2014, 55, 526–533.
  7. Cornelius, J.R.; Bukstein, O.; Salloum, I.; Clark, D. Alcohol and psychiatric comorbidity. Recent. Dev. Alcohol. Res. Alcohol. Treat. 2002, 16, 361–374.
  8. Grant, B.F.; Harford, T.C. Comorbidity between DSM-IV alcohol use disorders and major depression: Results of a national survey. Drug Alcohol. Depend. 1995, 39, 197–206.
  9. Neupane, S.P. Neuroimmune interface in the comorbidity between alcohol use disorder and major depression. Front. Immunol. 2016, 7, 655.
  10. Khalid, A.; Kunwar, A.R.; Rajbhandari, K.; Sharma, V.D.; Regmi, S.K. A study of prevalence and comorbidity of depression in alcohol dependence. Indian. J. Psychiatry 2000, 42, 434.
  11. Currie, S.R.; Patten, S.B.; Williams, J.V.; Wang, J.; Beck, C.A.; El-Guebaly, N.; Maxwell, C. Comorbidity of major depression with substance use disorders. Can. J. Psychiatry 2005, 50, 660–666.
  12. Luscher, B.; Shen, Q.; Sahir, N. The GABAergic deficit hypothesis of major depressive disorder. Mol. Psychiatry 2011, 16, 383–406.
  13. Koob, G.F. A role for GABA mechanisms in the motivational effects of alcohol. Biochem. Pharmacol. 2004, 68, 1515–1525.
  14. Koob, G.F. A role for GABA in alcohol dependence1. Adv. Pharmacol. 2006, 54, 205–229.
  15. Jo, S.; Yarishkin, O.; Hwang, Y.J.; Chun, Y.E.; Park, M.; Woo, D.H.; Bae, J.Y.; Kim, T.; Lee, J.; Chun, H. GABA from reactive astrocytes impairs memory in mouse models of Alzheimer’s disease. Nat. Med. 2014, 20, 886–896.
  16. Zurek, A.A.; Yu, J.; Wang, D.-S.; Haffey, S.C.; Bridgwater, E.M.; Penna, A.; Lecker, I.; Lei, G.; Chang, T.; Salter, E.W. Sustained increase in α5GABA A receptor function impairs memory after anesthesia. J. Clin. Investig. 2014, 124, 5437–5441.
  17. Woo, J.; Min, J.O.; Kang, D.-S.; Kim, Y.S.; Jung, G.H.; Park, H.J.; Kim, S.; An, H.; Kwon, J.; Kim, J. Control of motor coordination by astrocytic tonic GABA release through modulation of excitation/inhibition balance in cerebellum. Proc. Natl. Acad. Sci. USA 2018, 115, 5004–5009.
  18. Marowsky, A.; Rudolph, U.; Fritschy, J.-M.; Arand, M. Tonic inhibition in principal cells of the amygdala: A central role for α3 subunit-containing GABAA receptors. J. Neurosci. 2012, 32, 8611–8619.
  19. Kwak, H.; Koh, W.; Kim, S.; Song, K.; Shin, J.-I.; Lee, J.M.; Lee, E.H.; Bae, J.Y.; Ha, G.E.; Oh, J.-E. Astrocytes control sensory acuity via tonic inhibition in the thalamus. Neuron 2020, 108, 691–706.e10.
  20. Olsen, R.W.; Hanchar, H.J.; Meera, P.; Wallner, M. GABAA receptor subtypes: The “one glass of wine” receptors. Alcohol 2007, 41, 201–209.
  21. Weyand, T.G.; Boudreaux, M.; Guido, W. Burst and tonic response modes in thalamic neurons during sleep and wakefulness. J. Neurophysiol. 2001, 85, 1107–1118.
  22. Fogaça, M.V.; Duman, R.S. Cortical GABAergic Dysfunction in Stress and Depression: New Insights for Therapeutic Interventions. Front. Cell. Neurosci. 2019, 13, 87.
  23. Roberto, M.; Kirson, D.; Khom, S. The Role of the Central Amygdala in Alcohol Dependence. Cold Spring Harb. Perspect. Med. 2021, 11, a039339.
  24. Liljequist, S.; Engel, J. Effects of GABAergic agonists and antagonists on various ethanol-induced behavioral changes. Psychopharmacology 1982, 78, 71–75.
  25. Vengeliene, V.; Bilbao, A.; Molander, A.; Spanagel, R. Neuropharmacology of alcohol addiction. Br. J. Pharmacol. 2008, 154, 299–315.
  26. Cousins, M.S.; Roberts, D.C.; de Wit, H. GABA(B) receptor agonists for the treatment of drug addiction: A review of recent findings. Drug Alcohol. Depend. 2002, 65, 209–220.
  27. Janak, P.H.; Michael Gill, T. Comparison of the effects of allopregnanolone with direct GABAergic agonists on ethanol self-administration with and without concurrently available sucrose. Alcohol 2003, 30, 1–7.
  28. Grant, K.A.; Waters, C.A.; Green-Jordan, K.; Azarov, A.; Szeliga, K.T. Characterization of the discriminative stimulus effects of GABA(A) receptor ligands in Macaca fascicularis monkeys under different ethanol training conditions. Psychopharmacology 2000, 152, 181–188.
  29. Rassnick, S.; D’Amico, E.; Riley, E.; Koob, G.F. GABA antagonist and benzodiazepine partial inverse agonist reduce motivated responding for ethanol. Alcohol. Clin. Exp. Res. 1993, 17, 124–130.
  30. Jazvinscak Jembrek, M.; Vlainic, J. GABA receptors: Pharmacological potential and pitfalls. Curr. Pharm. Des. 2015, 21, 4943–4959.
  31. Sigel, E.; Steinmann, M.E. Structure, function, and modulation of GABAA receptors. J. Biol. Chem. 2012, 287, 40224–40231.
  32. Watanabe, M.; Maemura, K.; Kanbara, K.; Tamayama, T.; Hayasaki, H. GABA and GABA receptors in the central nervous system and other organs. Int. Rev. Cytol. 2002, 213, 1–47.
  33. Pinard, A.; Seddik, R.; Bettler, B. GABAB receptors: Physiological functions and mechanisms of diversity. Adv. Pharmacol. 2010, 58, 231–255.
  34. Lee, M.; Schwab, C.; Mcgeer, P.L. Astrocytes are GABAergic cells that modulate microglial activity. Glia 2011, 59, 152–165.
  35. Liu, J.; Feng, X.; Wang, Y.; Xia, X.; Zheng, J.C. Astrocytes: GABAceptive and GABAergic cells in the brain. Front. Cell. Neurosci. 2022, 16, 892497.
  36. Andersen, J.V.; Schousboe, A.; Wellendorph, P. Astrocytes regulate inhibitory neurotransmission through GABA uptake, metabolism, and recycling. Essays Biochem. 2023, 67, 77–91.
  37. Kilb, W.; Kirischuk, S. GABA release from astrocytes in health and disease. Int. J. Mol. Sci. 2022, 23, 15859.
  38. Lee, M.; McGeer, E.G.; McGeer, P.L. Mechanisms of GABA release from human astrocytes. Glia 2011, 59, 1600–1611.
  39. Schousboe, A.; Hertz, L.; Svenneby, G. Uptake and metabolism of GABA in astrocytes cultured from dissociated mouse brain hemispheres. Neurochem. Res. 1977, 2, 217–229.
  40. Schousboe, A.; Waagepetersen, H.S. Role of astrocytes in homeostasis of glutamate and GABA during physiological and pathophysiological conditions. Adv. Mol. Cell Biol. 2003, 31, 461–474.
  41. Schousboe, A.; Westergaard, N.; Sonnewald, U.; Petersen, S.; Yu, A.; Hertz, L. Regulatory role of astrocytes for neuronal biosynthesis and homeostasis of glutamate and GABA. Prog. Brain Res. 1992, 94, 199–211.
  42. Ishibashi, M.; Egawa, K.; Fukuda, A. Diverse Actions of Astrocytes in GABAergic Signaling. Int. J. Mol. Sci. 2019, 20, 2964.
  43. Roberts, E.; Frankel, S. γ-Aminobutyric acid in brain: Its formation from glutamic acid. J. Biol. Chem. 1950, 187, 55–63.
  44. Tao, R.; Davis, K.N.; Li, C.; Shin, J.H.; Gao, Y.; Jaffe, A.E.; Gondré-Lewis, M.C.; Weinberger, D.R.; Kleinman, J.E.; Hyde, T.M. GAD1 alternative transcripts and DNA methylation in human prefrontal cortex and hippocampus in brain development, schizophrenia. Mol. Psychiatry 2018, 23, 1496–1505.
  45. Yoon, B.E.; Woo, J.; Chun, Y.E.; Chun, H.; Jo, S.; Bae, J.Y.; An, H.; Min, J.O.; Oh, S.J.; Han, K.S. Glial GABA, synthesized by monoamine oxidase B, mediates tonic inhibition. J. Physiol. 2014, 592, 4951–4968.
  46. Losi, G.; Mariotti, L.; Carmignoto, G. GABAergic interneuron to astrocyte signalling: A neglected form of cell communication in the brain. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2014, 369, 20130609.
  47. Scimemi, A. Structure, function, and plasticity of GABA transporters. Front. Cell. Neurosci. 2014, 8, 161.
  48. Jin, X.T.; Galvan, A.; Wichmann, T.; Smith, Y. Localization and Function of GABA Transporters GAT-1 and GAT-3 in the Basal Ganglia. Front. Syst. Neurosci. 2011, 5, 63.
  49. Fattorini, G.; Catalano, M.; Melone, M.; Serpe, C.; Bassi, S.; Limatola, C.; Conti, F. Microglial expression of GAT-1 in the cerebral cortex. Glia 2020, 68, 646–655.
  50. Melone, M.; Ciappelloni, S.; Conti, F. A quantitative analysis of cellular and synaptic localization of GAT-1 and GAT-3 in rat neocortex. Brain Struct. Funct. 2015, 220, 885–897.
  51. Minelli, A.; DeBiasi, S.; Brecha, N.C.; Zuccarello, L.V.; Conti, F. GAT-3, a high-affinity GABA plasma membrane transporter, is localized to astrocytic processes, and it is not confined to the vicinity of GABAergic synapses in the cerebral cortex. J. Neurosci. 1996, 16, 6255–6264.
  52. Boddum, K.; Jensen, T.P.; Magloire, V.; Kristiansen, U.; Rusakov, D.A.; Pavlov, I.; Walker, M.C. Astrocytic GABA transporter activity modulates excitatory neurotransmission. Nat. Commun. 2016, 7, 13572.
  53. Andersen, J.V.; Schousboe, A. Milestone Review: Metabolic dynamics of glutamate and GABA mediated neurotransmission—The essential roles of astrocytes. J. Neurochem. 2023, 166, 109–137.
  54. Tritsch, N.X.; Granger, A.J.; Sabatini, B.L. Mechanisms and functions of GABA co-release. Nat. Rev. Neurosci. 2016, 17, 139–145.
  55. Murphy-Royal, C.; Ching, S.; Papouin, T. A conceptual framework for astrocyte function. Nat. Neurosci. 2023, 26, 1848–1856.
  56. Waagepetersen, H.S.; Sonnewald, U.; Schousboe, A. Compartmentation of glutamine, glutamate, and GABA metabolism in neurons and astrocytes: Functional implications. Neurosci. 2003, 9, 398–403.
  57. Carvalho, A.F.; Heilig, M.; Perez, A.; Probst, C.; Rehm, J. Alcohol use disorders. Lancet 2019, 394, 781–792.
  58. Lindberg, D.; Andres-Beck, L.; Jia, Y.F.; Kang, S.; Choi, D.S. Purinergic Signaling in Neuron-Astrocyte Interactions, Circadian Rhythms, and Alcohol Use Disorder. Front. Physiol. 2018, 9, 9.
  59. Yang, W.; Singla, R.; Maheshwari, O.; Fontaine, C.J.; Gil-Mohapel, J. Alcohol Use Disorder: Neurobiology and Therapeutics. Biomedicines 2022, 10, 1192.
  60. Griswold, M.G.; Fullman, N.; Hawley, C.; Arian, N.; Zimsen, S.R.; Tymeson, H.D.; Venkateswaran, V.; Tapp, A.D.; Forouzanfar, M.H.; Salama, J.S. Alcohol use and burden for 195 countries and territories, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet 2018, 392, 1015–1035.
  61. World Health Organization. Global Status Report on Alcohol and Health 2018; World Health Organization: Geneva, Switzerland, 2019.
  62. Collaborators, G.; Ärnlöv, J. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020, 396, 1223–1249.
  63. Koob, G.F.; Roberts, A.J.; Schulteis, G.; Parsons, L.H.; Heyser, C.J.; Hyytiä, P.; Merlo-Pich, E.; Weiss, F. Neurocircuitry targets in ethanol reward and dependence. Alcohol. Clin. Exp. Res. 1998, 22, 3–9.
  64. Augier, E.; Barbier, E.; Dulman, R.S.; Licheri, V.; Augier, G.; Domi, E.; Barchiesi, R.; Farris, S.; Nätt, D.; Mayfield, R.D.; et al. A molecular mechanism for choosing alcohol over an alternative reward. Science 2018, 360, 1321–1326.
  65. Koob, G.F.; Volkow, N.D. Neurobiology of addiction: A neurocircuitry analysis. Lancet Psychiatry 2016, 3, 760–773.
  66. Domi, E.; Domi, A.; Adermark, L.; Heilig, M.; Augier, E. Neurobiology of alcohol seeking behavior. J. Neurochem. 2021, 157, 1585–1614.
  67. Abrahao, K.P.; Salinas, A.G.; Lovinger, D.M. Alcohol and the brain: Neuronal molecular targets, synapses, and circuits. Neuron 2017, 96, 1223–1238.
  68. Koob, G.F.; Volkow, N.D. Neurocircuitry of addiction. Neuropsychopharmacology 2010, 35, 217–238.
  69. Spanagel, R.; Zink, M.; Sommer, W.H. Neurobiology of Alcohol Addiction. In Neuroscience in the 21st Century: From Basic to Clinical; Pfaff, D.W., Ed.; Springer: New York, NY, USA, 2013; pp. 2745–2773.
  70. Roberto, M.; Madamba, S.G.; Stouffer, D.G.; Parsons, L.H.; Siggins, G.R. Increased GABA release in the central amygdala of ethanol-dependent rats. J. Neurosci. 2004, 24, 10159–10166.
  71. Colombo, G.; Serra, S.; Brunetti, G.; Vacca, G.; Carai, M.A.; Gessa, G.L. Suppression by baclofen of alcohol deprivation effect in Sardinian alcohol-preferring (sP) rats. Drug Alcohol. Depend. 2003, 70, 105–108.
  72. GOLDSTEIN, D.B. Alcohol withdrawal reactions in mice: Effects of drugs that modify neurotransmission. J. Pharmacol. Exp. Ther. 1973, 186, 1–9.
  73. Hyytiä, P.; Koob, G.F. GABAA receptor antagonism in the extended amygdala decreases ethanol self-administration in rats. Eur. J. Pharmacol. 1995, 283, 151–159.
  74. Foster, K.L.; McKay, P.F.; Seyoum, R.; Milbourne, D.; Yin, W.; Sarma, P.; Cook, J.M.; June, H.L. GABAA and opioid receptors of the central nucleus of the amygdala selectively regulate ethanol-maintained behaviors. Neuropsychopharmacology 2004, 29, 269–284.
  75. Frye, G.D.; Mccown, T.J.; Breese, G.R. Characterization of susceptibility to audiogenic seizures in ethanol-dependent rats after microinjection of γ-aminobutyric acid (GABA) agonists into the inferior colliculus, substantia nigra or medial septum. J. Pharmacol. Exp. Ther. 1983, 227, 663.
  76. Cooper, B.; Viik, K.; Ferris, R.; White, H. Antagonism of the enhanced susceptibility to audiogenic seizures during alcohol withdrawal in the rat by gamma-aminobutyric acid (GABA) and” GABA-mimetic” agents. J. Pharmacol. Exp. Ther. 1979, 209, 396–403.
  77. Frye, G.D.; McCOWN, T.J.; Breese, G.R. Differential sensitivity of ethanol withdrawal signs in the rat to gamma-aminobutyric acid (GABA) mimetics: Blockade of audiogenic seizures but not forelimb tremors. J. Pharmacol. Exp. Ther. 1983, 226, 720–725.
  78. Valenzuela, C.F. Alcohol and neurotransmitter interactions. Alcohol. Health Res. World 1997, 21, 144–148.
  79. Mederos, S.; Perea, G. GABAergic-astrocyte signaling: A refinement of inhibitory brain networks. Glia 2019, 67, 1842–1851.
  80. Corbit, L.H.; Nie, H.; Janak, P.H. Habitual alcohol seeking: Time course and the contribution of subregions of the dorsal striatum. Biol. Psychiatry 2012, 72, 389–395.
  81. Barker, J.M.; Taylor, J.R. Habitual alcohol seeking: Modeling the transition from casual drinking to addiction. Neurosci. Biobehav. Rev. 2014, 47, 281–294.
  82. Olsen, R.W.; Liang, J. Role of GABAA receptors in alcohol use disorders suggested by chronic intermittent ethanol (CIE) rodent model. Mol. Brain 2017, 10, 45.
  83. Lovinger, D.M.; Kash, T.L. Mechanisms of neuroplasticity and ethanol’s effects on plasticity in the striatum and bed nucleus of the stria terminalis. Alcohol Res. Curr. Rev. 2015, 37, 109.
  84. Mederos, S.; Sánchez-Puelles, C.; Esparza, J.; Valero, M.; Ponomarenko, A.; Perea, G. GABAergic signaling to astrocytes in the prefrontal cortex sustains goal-directed behaviors. Nat. Neurosci. 2021, 24, 82–92.
  85. Lipton, D.M.; Gonzales, B.J.; Citri, A. Dorsal Striatal Circuits for Habits, Compulsions and Addictions. Front. Syst. Neurosci. 2019, 13, 28.
  86. Yin, H.H.; Knowlton, B.J. The role of the basal ganglia in habit formation. Nat. Rev. Neurosci. 2006, 7, 464–476.
  87. Kang, S.; Choi, D.S. Astrocyte adenosine signaling and neural mechanisms of goal-directed and habitual reward-seeking behaviors. Neuropsychopharmacology 2021, 46, 227–228.
  88. Mallet, N.; Micklem, B.R.; Henny, P.; Brown, M.T.; Williams, C.; Bolam, J.P.; Nakamura, K.C.; Magill, P.J. Dichotomous organization of the external globus pallidus. Neuron 2012, 74, 1075–1086.
  89. Hong, S.-I.; Kang, S.; Song, M.; Yang, M.; Baker, M.; Kang, S.; Lee, J.; Lee, S.W.; Choi, D.-S. Astrocytes in the external globus pallidus coordinate flexibility of action strategy. Sci. Adv. 2021, 9, eadh9239.
  90. Hong, S.I.; Kang, S.; Baker, M.; Choi, D.S. Astrocyte-neuron interaction in the dorsal striatum-pallidal circuits and alcohol-seeking behaviors. Neuropharmacology 2021, 198, 108759.
  91. Kang, S.; Hong, S.I.; Kang, S.; Song, M.; Yang, M.A.; Essa, H.; Baker, M.; Lee, J.; Bruce, R.A.; Lee, S.W.; et al. Astrocyte activities in the external globus pallidus regulate action-selection strategies in reward-seeking behaviors. Sci. Adv. 2023, 9, eadh9239.
  92. Chazalon, M.; Paredes-Rodriguez, E.; Morin, S.; Martinez, A.; Cristóvão-Ferreira, S.; Vaz, S.; Sebastiao, A.; Panatier, A.; Boué-Grabot, E.; Miguelez, C. GAT-3 dysfunction generates tonic inhibition in external globus pallidus neurons in parkinsonian rodents. Cell Rep. 2018, 23, 1678–1690.
  93. Ribak, C.E.; Tong, W.M.; Brecha, N.C. GABA plasma membrane transporters, GAT-1 and GAT-3, display different distributions in the rat hippocampus. J. Comp. Neurol. 1996, 367, 595–606.
  94. Morrow, A.L.; Suzdak, P.D.; Karanian, J.W.; Paul, S.M. Chronic ethanol administration alters gamma-aminobutyric acid, pentobarbital and ethanol-mediated 36Cl- uptake in cerebral cortical synaptoneurosomes. J. Pharmacol. Exp. Ther. 1988, 246, 158–164.
  95. Szmigielski, A.; Szmigielska, H.; Wejman, I. The effect of single and prolonged ethanol administration on the sensitivity of central GABA-A and benzodiazepine receptors in vivo. Pol. J. Pharmacol. Pharm. 1992, 44, 271–280.
  96. Roberts, A.J.; Cole, M.; Koob, G.F. Intra-amygdala muscimol decreases operant ethanol self-administration in dependent rats. Alcohol. Clin. Exp. Res. 1996, 20, 1289–1298.
  97. Marti-Prats, L.; Belin-Rauscent, A.; Fouyssac, M.; Puaud, M.; Cocker, P.J.; Everitt, B.J.; Belin, D. Baclofen decreases compulsive alcohol drinking in rats characterized by reduced levels of GAT-3 in the central amygdala. Addict. Biol. 2021, 26, e13011.
Subjects: Neurosciences
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to : , , , ,
View Times: 194
Revisions: 3 times (View History)
Update Date: 20 Feb 2024